Clinical Trial Update: Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating AZD4547 for recurrent malignant glioma with FGFR-TACC gene fusions has completed Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idh-wildtype Gliomas

Drugs mentioned

• AZD4547

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion, Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion | Phase 1, Phase 2 | Status: COMPLETED